MediWound Ltd.
corporate_fare Company Profile
MediWound Ltd. (NASDAQ:MDWD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for MDWD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-22, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for MDWD spans 6-K, 20-F.
Recent high-impact activity:
- MediWound Secures $3.3M U.S. Funding for Room-Temp NexoBrid
- MediWound Pegs $1B Peak Sales for EscharEx in $4B Debridement Market
- MediWound Q2 Revenue Misses, Cash Burn Accelerates; Guidance Reaffirmed
- MediWound Q2 Revenue Falls 46% to $3.1M, Reaffirms $24–26M Full-Year Guidance
- Key EscharEx Phase III Trial Delayed by a Quarter; MediWound Q1 Revenue Missed Estimates
Financial Snapshot
Short Interest & Short Volume
14.39 days to coverFINRA reported short interest of 1,813,385 shares in MDWD as of the September 15, 2026 settlement, a 11.4% increase from the prior period — about 14.4 days to cover at its recent average daily volume. On October 2, 2026, 91.6% of MDWD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
MDWD files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.